On Dec. 28, 2021, Novavax and Serum Institute of India announced that the Drugs Controller General of India had granted emergency use authorization (EUA) for Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant.

The vaccine will be manufactured and marketed in India by SII under the brand name Covovax.